CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients

The CXCR4 receptor and its ligand CXCL12 (also named stromal cell-derived factor 1, SDF1) have a critical role in chemotaxis and homing, key steps in cancer metastasis. Although myofibroblasts expressing CXCL12 are associated with the presence of axillary metastases in HER2 breast cancers (BC), the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lefort, S, Thuleau, A, Kieffer, Y, Sirven, P, Bieche, I, Marangoni, E, Vincent-Salomon, A, Mechta-Grigoriou, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340801/
https://www.ncbi.nlm.nih.gov/pubmed/27669438
http://dx.doi.org/10.1038/onc.2016.284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340801/
https://www.ncbi.nlm.nih.gov/pubmed/27669438
http://dx.doi.org/10.1038/onc.2016.284

Ejemplares similares